Robert Robbins is a partner in Robbins Geller Rudman & Dowd LLP’s Boca Raton office. He focuses his practice on investigating securities fraud, initiating securities class actions, and helping institutional and individual shareholders litigate their claims to recover investment losses caused by fraud. Representing shareholders in all aspects of class actions brought pursuant to the federal securities laws, Robbins provides counsel in numerous securities fraud class actions across the country, helping secure significant recoveries for investors.
Lawdragon Honors
| Honor | Year | Practice |
|---|---|---|
| The 2026 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2026 | Securities Litigation |
| The 2026 Lawdragon 500 Leading Litigators in America | 2026 | Financial Litigation |
| The 2025 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2025 | Securities Litigation |
| The 2025 Lawdragon 500 Leading Litigators in America | 2025 | Financial Litigation |
| The 2024 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2024 | Securities Litigation |
| The 2024 Lawdragon 500 Leading Litigators in America | 2024 | Financial Litigation |
| The 2023 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2023 | Securities Litigation |
| The 2022 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2022 | Securities Litigation |
| The 2021 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2021 | Securities Litigation |
| The 2020 Lawdragon 500 Leading Plaintiff Financial Lawyers | 2020 | Securities Litigation |
| Lawdragon 500 Leading Plaintiff Financial Lawyers | 2019 | Securities Litigation |
Recently, Robbins was a key member of the Robbins Geller litigation team that secured a $1.21 billion settlement in In re Valeant Pharms. Int’l, Inc. Sec. Litig., a case that Vanity Fair reported as “the corporate scandal of its era” that had raised “fundamental questions about the functioning of our health-care system, the nature of modern markets, and the slippery slope of ethical rationalizations.” This is the ninth largest securities class action settlement ever and the largest against a pharmaceutical manufacturer. Robbins has also been a member of Robbins Geller litigation teams responsible for securing hundreds of millions of dollars in securities class action settlements, including: Hospira ($60 million recovery); 3D Systems ($50 million); CVS Caremark ($48 million recovery); Baxter International ($42.5 million recovery); Grubhub ($42 million); R.H. Donnelley ($25 million recovery); Spiegel ($17.5 million recovery); TECO Energy ($17.35 million recovery); AFC Enterprises ($17.2 million recovery); Accretive Health ($14 million recovery); Lender Processing Services ($14 million recovery); Lexmark Int’l ($12 million); Imperial Holdings ($12 million recovery); Mannatech ($11.5 million recovery); Newpark Resources ($9.24 million recovery); CURO Group ($8.98 million); Gilead Sciences ($8.25 million recovery); TCP International ($7.175 million recovery); Cryo Cell International ($7 million recovery); Gainsco ($4 million recovery); and Body Central ($3.425 million recovery).
Robbins has been named a Leading Litigator in America and a Leading Plaintiff Financial Lawyer by Lawdragon. Before joining the Firm, he prosecuted a wide variety of securities and consumer class actions with Geller Rudman, PLLC. He began his legal career as a commercial litigator for one of the largest law firms in the United States. During that time, Robbins aggressively litigated complex actions in both state and federal court, including securities class action matters, commercial contract matters, and commercial real estate litigation.
Robbins earned his Bachelor of Science degree from the University of Florida. He then graduated with a Juris Doctor degree, with high honors, from the University of Florida College of Law, where he was a member of the Journal of Law and Public Policy and a member of Phi Delta Phi. Upon graduation, Robbins was selected as a member of the Order of the Coif.